Iovance Biotherapeutics (IOVA) Hits New 12-Month High at $18.68

Iovance Biotherapeutics Inc (NASDAQ:IOVA) hit a new 52-week high during mid-day trading on Thursday . The company traded as high as $18.68 and last traded at $17.75, with a volume of 877200 shares trading hands. The stock had previously closed at $17.75.

IOVA has been the topic of a number of recent research reports. HC Wainwright set a $16.00 target price on Iovance Biotherapeutics and gave the company a “buy” rating in a research report on Monday, October 30th. BidaskClub lowered Iovance Biotherapeutics from a “buy” rating to a “hold” rating in a research report on Friday, December 22nd. ValuEngine raised Iovance Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. Jefferies Group reissued a “buy” rating on shares of Iovance Biotherapeutics in a research report on Sunday, October 29th. Finally, FBR & Co reissued a “buy” rating and issued a $17.50 target price on shares of Iovance Biotherapeutics in a research report on Wednesday, October 25th. Two research analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $18.75.

Several large investors have recently bought and sold shares of the business. TIAA CREF Investment Management LLC increased its position in shares of Iovance Biotherapeutics by 24.4% during the 4th quarter. TIAA CREF Investment Management LLC now owns 321,926 shares of the biotechnology company’s stock worth $2,575,000 after purchasing an additional 63,135 shares during the last quarter. Teachers Advisors LLC increased its position in shares of Iovance Biotherapeutics by 10.3% during the 4th quarter. Teachers Advisors LLC now owns 162,165 shares of the biotechnology company’s stock worth $1,297,000 after purchasing an additional 15,143 shares during the last quarter. California State Teachers Retirement System increased its position in shares of Iovance Biotherapeutics by 13.5% during the 4th quarter. California State Teachers Retirement System now owns 97,044 shares of the biotechnology company’s stock worth $776,000 after purchasing an additional 11,559 shares during the last quarter. Perceptive Advisors LLC increased its position in shares of Iovance Biotherapeutics by 1.1% during the 4th quarter. Perceptive Advisors LLC now owns 4,776,114 shares of the biotechnology company’s stock worth $38,208,000 after purchasing an additional 50,000 shares during the last quarter. Finally, Two Sigma Investments LP acquired a new position in shares of Iovance Biotherapeutics during the 4th quarter worth approximately $226,000. 65.08% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: This article was published by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this article on another site, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The original version of this article can be viewed at https://stocknewstimes.com/2018/02/22/iovance-biotherapeutics-iova-hits-new-12-month-high-at-18-68.html.

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc, formerly Lion Biotechnologies, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. The Company’s lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes, which are T cells derived from patients’ tumors, for the treatment of metastatic melanoma.

Receive News & Ratings for Iovance Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply